Roche's PD-L1 mAb produces responses in TNBC

Roche (SIX:ROG; OTCQX:RHHBY) reported a 70.8% objective response rate (ORR) in a Phase Ib study of atezolizumab ( MPDL3280A) to treat triple-negative breast cancer. The human mAb against PD-L1 produced responses in both PD-L1-positive and negative patients.

Roche said there were 16 partial responses and one complete response in the 24-patient study. Four of seven PD-L1-negative patients and seven of nine PD-L1 expressors had responses; the remainder had unknown PD-L1 status. Eight of nine patients receiving their first treatment for metastatic disease had responses, including one complete response. ...